Tumor response
14 evaluable patients at doses upto 390mg/m2
Stable disease observed in 3 patients ranging from 16 – 51 weeks
Of these, the patient with stable disease at 51 weeks has experienced 20% shrinkage of a pulmonary lesion
Previous slide
Next slide
Back to first slide
View graphic version